| Contents Vear ended 31 December 2025 |
|
|---|---|
| Page | |
| Legal and administrative information | 2 |
| Summary | 3 |
| Founder's Statement | 5 |
| Report of the Trustees | 6 |
| Report of the Independent Auditors | 14 |
| Consolidated Statement of Financial Activities | 17 |
| Balance Sheets | 18 |
| Consolidated Cash Flow Statement | 19 |
| Notes forming part of the Financial Statements | 20 |
26/10/2026
| Notes Income Income from donations 2 Income from investments Total Expenditure Charitable activities 3 Raising funds 4 Total Net movement infunds Transfer of funds 8 Funds brought forward Funds carried forward |
Unrestricted £ 218,750 1,320 220,070 116,790 70,870 187,660 32,410 235,377 267,787 |
Restricted £ 3,264,413 63,893 3,328,306 1,091,508 13,072 1,104,580 2,223,726 4,890,175 7,113,901 |
2025 Total £ 3,483,163 65,213 3,548,376 1,208,298 83,942 1,292,240 2,256,136 5,125,552 7,381,688 |
Unrestricted £ 257,450 257,450 92,494 129,499 221,993 35,457 199,920 235,377 |
Restricted £ 4,550,018 43,295 4,593,313 1,155,172 33,789 1,188,961 3,404,352 1,485,823 4,890,175 |
2024 Total £ 4,807,468 43,295 |
|---|---|---|---|---|---|---|
| 4,850,763 | ||||||
| 1,247,666 163,288 |
||||||
| 1,410,954 | ||||||
| 3,439,809 1,685,743 |
||||||
| 5,125,552 |
| Notes Fixed assets Investments 5 Current assets Cash at bank Other debtors 6 Current asset investments 7 Creditors: Amounts falling due within one year 8 Net current assets Total assets less current liabilities Creditors: amounts falling due after more than one year 9 Total net assets The funds of the charity Unrestricted income funds Restricted income funds Total funds |
Group 2025 2024 £ £ 899,841 317,752 4,027,086 1,852,797 90,389 2,119,345 4,500,000 2,500,000 8,617,475 6,472,142 (1,668,905) (1,169,204) 6,948,570 5,302,938 7,848,411 5,620,690 (466,723) (495,138) 7,381,688 5,125,552 267,787 235,377 7,113,901 4,890,175 7,381,688 5,125,552 |
Charity 2025 2024 £ £ 899,941 317,852 3,908,795 1,675,292 90,389 2,119,345 4,500,000 2,500,000 8,499,184 6,294,637 (1,550,714) (991,799) 6,948,470 5,302,838 7,848,411 5,620,690 (466,723) (495,138) 7,381,688 5,125,552 299,484 267,074 7,082,204 4,858,478 7,381,688 5,125,552 |
Charity 2025 2024 £ £ 899,941 317,852 3,908,795 1,675,292 90,389 2,119,345 4,500,000 2,500,000 8,499,184 6,294,637 (1,550,714) (991,799) 6,948,470 5,302,838 7,848,411 5,620,690 (466,723) (495,138) 7,381,688 5,125,552 299,484 267,074 7,082,204 4,858,478 7,381,688 5,125,552 |
|---|---|---|---|
| 1,675,292 2,119,345 2,500,000 |
|||
| 6,294,637 (991,799) |
|||
| 5,302,838 | |||
| 5,620,690 (495,138) |
|||
| 5,125,552 | |||
| 267,074 4,858,478 |
|||
| 5,125,552 |
| 2025 £ Net movement of funds from operating activities 2,256,136 Impairment of fixed asset investments 100,000 Purchase of fixed asset investments (682,089) Increase in debtors/ investments (Notes 6 and 7) 28,956 Increase in creditors (Notes 8 and 9) 471,287 Net cash inflow from operations 2,174,289 Cash at the beginning of the year 1,852,797 Cash at the end of the year 4,027,086 |
2024 £ 3,439,809 100,000 (299,325) (2,963,898) 233,702 |
|---|---|
| 510,288 1,342,509 |
|
| 1,852,797 |
| 3. Charitable activities Research projects: University of Minnesota - Nanocol Gene Editing Trial - UC3 Madrid Base & Prime Editing strategies for RDEB University of Colorado - Spray on Skin EB Cancer Therapy Oligo EB Graft lnserm - SIRNA JEB Airway Disease Decorin Bespoke Therapy mRNA-based base editing Chemoprevention James Lind Alliance Nanocure Other costs: Impairment losses Support costs: Administration costs Bank charges Audit Charitable Events - restricted Research Events - restricted Insurance 4. Raising funds Fund raising and marketing Fundraising administration costs 2025 £ (26) (1,525) 38,166 235 326,211 214,843 10,000 358,656 100,000 102,206 272 13,035 44,561 387 1,277 1,208,298 2025 £ 36,197 47,745 83,942 |
2024 £ 38,802 350,730 (558,897) 147,033 638,664 66,767 80,000 16,951 267,198 100,000 80,490 274 10,532 6,625 1,300 1,197 1,247,666 |
|---|---|
| 2024 £ 34,518 128,770 163,288 |
| Fixed asset investments-held by Group and Charity Social investments-unlisted Cost at 1 January 2025 Additions Cost at 31 December 2025 Impairment Charge for the year Net book value At 31 December 2025 At 31 December 2024 Shares in Group undertakings held by Charity Cost at 1 January 2025 Cost at 31 December 2025 Net book value Cost at 31 December 2024 |
2025 £ 317,752 682,089 999,841 (100,000) 899,841 317,752 2025 £ 100 100 100 |
2024 £ 118,427 299,325 417,752 (100,000) |
|---|---|---|
| 317,752 118,427 |
||
| 2024 £ 100 100 |
||
| 100 |
| Debtors | Group | Charity | ||
|---|---|---|---|---|
| 2025 | 2024 | 2025 | 2024 | |
| £ | £ | £ | £ | |
| Other debtors | 90,389 | 2,119,345 | 90,389 | 2,119,345 |
| Current Asset investments Treasury Bonds Creditors: amounts falling due within one year Trade creditors Amounts owed to intercompany Unpaid share capital Committed grants |
Group 2025 2024 £ £ 4,500,000 2,500,000 Group 2025 2024 £ £ 240,613 258,473 1,428,292 910,731 1,668,905 1,169,204 |
Charity 2025 2024 £ £ 4,500,000 2,500,000 Charity 2025 2024 £ £ 18,192 15,005 104,130 65,963 100 100 1,428,292 910,731 1,550,714 991,799 |
2024 £ 2,500,000 |
|---|---|---|---|
| 991,799 |
| Group 2025 2024 £ £ 466,723 495,138 466,723 495,138 |
Charity 2025 2024 £ £ 466,723 495,138 466,723 495,138 |
Charity 2025 2024 £ £ 466,723 495,138 466,723 495,138 |
|---|---|---|
| 495,138 |
| 10. Fund balances- Current year Balance brought forward Income Expenditure Inter fund transfer Balance carried forward Represented by: Fixed assets Cash at bank Other net assets/liabilities Brought Current year Forward £ Research Projects Therapy for RDEBsec 50,000 Gene Editing Trial EB Cancer Therapy Decorin SIRNA 37,103 mRNA-based base editing James Lind Alliance Nanocure Social Investments Nonsense Therapeutics 100,000 Healome Eliksa Replay FIBRX Derm Other Social Investments 118,427 Nova Anchora 99,325 Other Research Funds Unassigned Research Funds 557,360 Other Restricted Funds ABE Fund 424,756 Translational Fund 3,472,549 Ebolution Fund Funds for Fundraiser 5,280 Research Events Children's Fund 25,375 4,890,175 |
Income £ 103,908 200,000 100,000 114,632 74,890 192,568 283,859 304,073 1,525,411 378,165 800 50,000 3,328,306 |
Expenditure £ (214,843) 26 1,525 (235) (326,211) (10,000) (358,656) (13,072) (38,166) (387) (44,561) (1,004,580) |
Unrestricted Funds £ 235,377 220,070 (187,660) 267,787 267,787 267,787 Gains/Losses £ (100,000) (100,000) |
Restricted Funds £ 4,890,175 3,328,306 (1,104,580) 7,113,901 899,841 3,759,299 2,454,761 7,113,901 Transfers £ 164,843 (26) (1,525) 235 222,303 10,000 358,656 (754,486) |
Total £ 5,125,552 3,548,376 (1,292,240) 7,381,688 899,841 4,027,086 2,454,761 7,381,688 Carried Forward £ 37,103 200,000 100,000 114,632 74,890 192,568 118,427 99,325 86,733 715,757 4,959,794 378,165 5,280 413 30,814 7,113,901 |
Total £ 5,125,552 3,548,376 (1,292,240) 7,381,688 899,841 4,027,086 2,454,761 7,381,688 Carried Forward £ 37,103 200,000 100,000 114,632 74,890 192,568 118,427 99,325 86,733 715,757 4,959,794 378,165 5,280 413 30,814 7,113,901 |
|---|---|---|---|---|---|---|
| 7,113,901 |
| 10 Fund balances (Continued) Previous Year Balance brought forward Income Expenditure Inter fund transfer Balance carried forward Represented by: Fixed assets Cash at bank Other net assets/liabilities Brought Previous year Forward £ Research Projects Therapy for RDEB~~sec~~ 50,000 EB Graft Gene Editing Trial Spray on Skin Base & prime editing strategies for RDEB EB Cancer Therapy Bespoke Therapy JEB Airway Disease Decorin SIRNA Social Investments Nonsense Therapeutics (ABE Fund) Other Social Investments 118,427 Nova Anchora Other Research Funds Unassigned Research Funds 198,300 Other Restricted Funds ABE Fund 26,818 Translational Fund 1,086,078 Funds for Fundraiser 6,200 Research Events Children's Fund 1,485,823 |
Income £ 37,103 108,631 37,103 200,000 99,325 621,910 412,807 3,025,134 1,300 50,000 4,593,313 |
Expenditure £ (66,767) (38,802) 558,897 (350,730) (147,033) (267,198) (80,000) (16,951) (14,869) (638,663) (920) (1,300) (24,625) (1,088,961) |
Unrestricted Funds £ 199,920 257,450 (221,993) 235,377 235,377 235,377 Gains/Losses £ (100,000) (100,000) |
Restricted Funds £ 1,485,823 4,593,313 (1,188,961) 4,890,175 317,752 1,617,420 2,955,003 4,890,175 Transfers £ 66,767 38,802 (596,000) 242,099 147,033 267,198 80,000 16,951 (262,850) |
Total £ 1,685,743 4,850,763 (1,410,954) 5,125,552 317,752 1,852,797 2,955,003 5,125,552 Carried Forward £ 50,000 37,103 100,000 118,427 99,325 557,360 424,756 3,472,549 5,280 25,375 4,890,175 |
|---|---|---|---|---|---|
| Therapy for RDEB~~sec~~ EB Graft Gene Editing Trial Spray on Skin Base & prime editing strategies for RDEB EB Cancer Therapy Bespoke Therapy JEB Airway Disease Decorin SIRNA Social Investments Nonsense Therapeutics (ABE Fund) Other Social Investments Nova Anchora Other Research Funds Unassigned Research Funds Other Restricted Funds ABE Fund Translational Fund Funds for Fundraiser Research Events Children's Fund |